Progressive Disease

WEST PALM BEACH, Fla. — More than a century of scientific research has shed light on the neuroimmune interaction in multiple sclerosis, which will be key for the development of disease-specific therapies, according to Jack P. Antel, MD.

INDIANAPOLIS — Although early detection of keratoconus is critical, it is also important to understand how to manage later-onset or progressive disease in older patients, according to a lecture at Academy 2024.

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial.

Individuals who ranked highest on a scale measuring social vulnerability by location had a poorer prognosis following colorectal resection, according to a presentation at Southern Surgical Association Annual Meeting.

For most of us doctors, it’s the last thing we look at before bed and the first thing when we wake up: the screen of our smartphone or tablet.

SAN DIEGO — Intermittent calorie restriction in patients with relapsing-remitting MS was associated with positive physical and cognitive outcomes after 12 weeks compared with an unrestricted diet, according to a researcher at ACTRIMS 2023.

A vital part of glaucoma management is assessing patients for the possibility of progressive disease.

Patients with primary progressive MS treated continuously with ocrelizumab saw greater benefit in regard to measures of disease progression compared with patients who switched from placebo during an open-label extension of the ORATORIO trial.

The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based upon the positive results of the MPACT trial in the metastatic setting. Interestingly, around the same time as the MPACT trial, FOLFIRINOX also showed improved OS in the metastatic setting compared with single-agent gemcitabine. Although median survival with FOLFIRINOX appeared to be numerically superior than with gemcitabine and nab-paclitaxel, subsequent real-world analyses indicated no significant differences in OS or time to treatment failure between the two regimens. It is therefore surprising that although the adjuvant FOLFIRINOX study was positive, the adjuvant gemcitabine and nab-paclitaxel trial was not.

LAS VEGAS – EyeEco announced the addition of several new patented products to its line of products focused on at-home eye hydration here at Vision Expo West.